3 Top Margin Expansion Stocks to Watch for Future Multibagger Potential: BHEL, Laurus Labs and Lupin
- October 19, 2026
- Posted by: Manan Bisht
- Category: Best Stocks
BHEL Rs 434.60. Laurus Labs Rs 2,060.10. Lupin Rs 1,961.60. Market caps from Rs 89,592 crore to Rs 1.51 lakh crore. Data as of 16 Oct 2026.
Quick Answer
BHEL, Laurus Labs and Lupin are the 3 picks in this margin expansion stocks watchlist, with market caps between Rs 89,592 crore and Rs 1.51 lakh crore. BHEL stands out for the fastest profit growth, 37.73% a year since FY22, while Laurus Labs offers the strongest latest-quarter profit growth at 124.73%. PE ratios run from 16.14 to 100.10, so compare each one with its industry PE before investing. All figures are as of 16 October 2026.
Margin expansion stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. BHEL, Laurus Labs and Lupin meet that test, with market caps from Rs 89,592 crore to Rs 1.51 lakh crore and BHEL offering the fastest profit growth, 37.73% a year since FY22. In each of these companies, FY26 net profit grew at least 25 percentage points faster than revenue.
This list covers companies whose FY26 net profit growth beat revenue growth by more than 25 percentage points, with rising revenue and complete, verifiable financials, ranked by market capitalisation. Not every name here is a largecap, so the list takes the leading companies of the sector by market capitalisation. Investors screening margin expansion stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 16 October 2026 and are drawn from NSE and BSE data and company filings.
Click Here – Get Free Investment Predictions
What Are Margin Expansion Stocks and Why Do They Attract Multibagger Interest?
Margin expansion stocks are shares of companies where profit has grown much faster than sales. That gap shows that each rupee of revenue now brings in more profit, thanks to better pricing, product mix or cost control.
Rising margins are one of the strongest drivers of earnings growth because the effect builds on top of higher sales. Businesses that keep improving margins are the ones investors compare in margin expansion stocks.
Margin Expansion Stocks at a Glance: Price, Market Cap, PE and ROE
Prices are closing prices as of 16 October 2026. Lupin combines the lowest PE of the group, 16.14, with the highest return on equity, 23.76%.
| Stock | CMP (Rs) | Market Cap (Rs Cr) | PE | Industry PE | ROE | Debt to Equity | 52-Week Range (Rs) |
|---|---|---|---|---|---|---|---|
| Bharat Heavy Electricals | 434.60 | 1,51,365 | 52.56 | 45.89 | 10.76% | 0.23 | 229.54 to 464.00 |
| Laurus Labs | 2,060.10 | 1,09,143 | 100.10 | 36.42 | 16.77% | 0.48 | 864.70 to 2,085.90 |
| Lupin | 1,961.60 | 89,592 | 16.14 | 36.42 | 23.76% | 0.29 | 1,900.00 to 2,529.50 |
BHEL: 37.73% Profit CAGR Since FY22
Bharat Heavy Electricals is a government-owned maker of power generation, transmission, industrial and transportation equipment. It reported FY26 revenue of Rs 34,589.83 crore, up 20.08% year on year, and net profit of Rs 1,600.26 crore, up 199.73%. Net profit has compounded at 37.73% a year since FY22, while revenue has grown 12.54% a year. Operating margin was 10.18% in FY26. The debt-to-equity ratio is 0.23.
In the September 2026 quarter, revenue rose 24.28% to Rs 9,553.01 crore and net profit grew 118.98% to Rs 820.94 crore. The share price has gained 488.34% over five years and 86.13% over the past year. Domestic institutions raised their holding from 18.62% in September 2025 to 21.88% in September 2026. The stock trades at a PE of 52.56 against an industry PE of 45.89.
Laurus Labs: Revenue Up 22.01% in FY26
Laurus Labs makes active pharmaceutical ingredients and formulations and offers contract development and manufacturing services. It reported FY26 revenue of Rs 6,867.85 crore, up 22.01% year on year, and net profit of Rs 889.85 crore, up 151.08%. Revenue has compounded at 8.53% a year since FY22. Operating margin was 26.90% in FY26. The debt-to-equity ratio is 0.48.
The stock trades at a PE of 100.10 against an industry PE of 36.42, with a return on equity of 16.77%. In the June 2026 quarter, revenue rose 28.83% to Rs 2,035.49 crore and net profit grew 124.73% to Rs 361.99 crore. The share price has gained 221.40% over five years and 137.53% over the past year. Domestic institutions raised their holding from 11.94% in June 2025 to 13.74% in June 2026.
Lupin: Revenue Up 26.76% in FY26
Lupin is a global pharmaceutical company with a large presence in the United States, India and other markets across generics, branded drugs and respiratory products. It reported FY26 revenue of Rs 29,038.95 crore, up 26.76% year on year, and net profit of Rs 5,355.47 crore, up 61.98%. Revenue has compounded at 14.98% a year since FY22. Operating margin was 31.06% in FY26. The debt-to-equity ratio is 0.29.
In the June 2026 quarter, revenue rose 32.45% to Rs 8,407.21 crore and net profit grew 16.01% to Rs 1,416.98 crore. The share price has gained 111.00% over five years. Foreign investors raised their holding from 21.25% in June 2025 to 22.42% in June 2026. The stock trades at a PE of 16.14 against an industry PE of 36.42, below the sector average, with a return on equity of 23.76%.
Margin Expansion Stocks: Financial Comparison on Growth and Margins
The table compares scale and growth across these margin expansion stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.
| Stock | Revenue (Rs Cr) | Net Profit (Rs Cr) | Revenue Growth (YoY) | 4-Year Revenue CAGR | Latest Quarter Revenue Growth | Operating Margin (Latest Quarter) |
|---|---|---|---|---|---|---|
| BHEL | 34,589.83 | 1,600.26 | 20.08% | 12.54% | 24.28% | 13.94% |
| Laurus Labs | 6,867.85 | 889.85 | 22.01% | 8.53% | 28.83% | 31.95% |
| Lupin | 29,038.95 | 5,355.47 | 26.76% | 14.98% | 32.45% | 31.40% |
Check the Univest Screener for live data on these margin expansion stocks
Institutional Holding in BHEL, Laurus Labs and Lupin
Institutional holding shows who is backing these margin expansion stocks alongside the promoter. The table uses the latest reported quarter for each. Lupin has the deepest institutional backing, with FII and DII together holding 47.07% as of June 2026. Domestic institutions increased their holding over the past year in BHEL (from 18.62% to 21.88%) and Laurus Labs (from 11.94% to 13.74%).
| Stock | Promoter | FII | DII | Public | Quarter |
|---|---|---|---|---|---|
| BHEL | 58.17% | 9.94% | 21.88% | 10.02% | September 2026 |
| Laurus Labs | 27.47% | 28.00% | 13.74% | 30.78% | June 2026 |
| Lupin | 46.85% | 22.42% | 24.65% | 6.08% | June 2026 |
Risks to Weigh in Margin Expansion Stocks
Being careful with margin expansion stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:
- Margins can move with input costs and pricing.
- Growth can ease as the base gets larger.
- Valuation: Laurus Labs trades at a PE of 100.10 against an industry PE of 36.42, so earnings need to keep growing to support the price.
- Concentration: Holding all 3 names puts the allocation in one sector, so size each position to match your risk appetite.
How to Choose Between Margin Expansion Stocks
Picking from margin expansion stocks comes down to four checks, applied in order.
- Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
- Compare each PE with the industry PE (36.42 to 45.89) and ask whether the growth rate justifies any gap.
- Track the operating margin, revenue growth and net profit growth in every quarterly result.
- Stagger entries across quarters and review institutional holding every reporting season.
Download the Univest iOS App or Univest Android App to track BHEL, Laurus Labs and Lupin live prices.
Conclusion
Among margin expansion stocks, BHEL stands out for the fastest profit growth, 37.73% a year since FY22, Laurus Labs for the strongest latest-quarter profit growth at 124.73% and Lupin for the highest return on equity at 23.76%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing margin expansion stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Margin Expansion Stocks to Watch
Which are the best margin expansion stocks to watch for multibagger potential?
Ans. BHEL, Laurus Labs and Lupin are the 3 names this list highlights, with market caps of Rs 1,51,365 crore, Rs 1,09,143 crore and Rs 89,592 crore respectively. BHEL is notable for the fastest profit growth, 37.73% a year since FY22. Laurus Labs stands out for the strongest latest-quarter profit growth at 124.73%. Lupin offers the highest return on equity at 23.76%. These are watchlist names for margin expansion stocks, not recommendations, so match each one to your own risk profile and time horizon.
Is Lupin a good stock for long-term investors?
Ans. Lupin has a return on equity of 23.76%, a PE of 16.14 against an industry PE of 36.42 and a market cap of Rs 89,592 crore. FY26 revenue rose 26.76%, and June 2026 quarter net profit grew 16.01%. Long-term returns in margin expansion stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.
Can BHEL become a multibagger from here?
Ans. BHEL has already gained 488.34% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in margin expansion stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 37.73% a year since FY22, and FY26 revenue rose 20.08%. At a PE of 52.56 against an industry PE of 45.89, valuation should be checked against that growth before investing.
What is the market cap of BHEL, Laurus Labs and Lupin?
Ans. As of 16 October 2026, BHEL has a market cap of Rs 1,51,365 crore, Laurus Labs has a market cap of Rs 1,09,143 crore and Lupin has a market cap of Rs 89,592 crore. BHEL is the largest of the group. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on margin expansion stocks.
What are the risks of investing in margin expansion stocks?
Ans. The main risks are input cost swings, pricing pressure and margins that stop improving. Companies with varied products and strong order books handle these better. Laurus Labs trades at a PE of 100.10 against an industry PE of 36.42, so earnings growth needs to hold up.
Why is Laurus Labs trading at a PE of 100.10?
Ans. Laurus Labs’ PE of 100.10 compares with an industry PE of 36.42. The market is paying a premium for a return on equity of 16.77%, latest-quarter profit growth of 124.73% and FY26 revenue growth of 22.01%, which also means the stock is more sensitive if growth slows. Investors in margin expansion stocks who are comfortable with higher valuation risk may prefer to stagger purchases instead of investing in one go.
How much do institutions hold in BHEL, Laurus Labs and Lupin?
Ans. As of the latest reported quarter, FII and DII together hold 31.82% of BHEL (9.94% and 21.88%), 41.74% of Laurus Labs (28.00% and 13.74%) and 47.07% of Lupin (22.42% and 24.65%). Rising institutional holding is a useful signal in margin expansion stocks, though it should be read with earnings trends rather than on its own.
